BRACE COVID-19-Specific vaccine sub-study (BCOS)

With philanthropic support from the Bill & Melinda Gates Foundation, this is a sub-study to the Murdoch Children’s Research Institute’s trial of Bacille Calmette-Guérin (BCG) vaccine to reduce the impact of COVID-19. By recruiting existing BRACE trial participants for the sub-study, researchers are seeking answers to these key questions:

BCOS Australia and Brazil

Does BCG vaccination, by boosting the immune system, improve the response to Pfizer, AstraZeneca and CoronaVac?

BCOS Brazil

Is it possible to predict who remains susceptible to SARS-CoV-2 variants despite previous COVID-19 disease or COVID-19-specific vaccination?

 

Projects Brace team Australian sub-study participants

  • Are participants in the main BRACE trial
  • Are healthcare workers at the Royal Children’s Hospital, Melbourne, Epworth HealthCare, Women's and Children's Hospital, Adelaide or the Royal Adelaide Hospital
  • Had not had their COVID-19-specific vaccine at the time of enrolment
  • Have not previously been diagnosed with COVID-19 at the time of enrolment

How it worked

BCOS participants attended one, two, or three vaccine sub-study clinic visits and provided a blood sample each time. The number of visits depended on the type of COVID-19-specific vaccine received. Where possible, we combined the visits with regular BRACE trial 3-monthly clinic visits.

Participants completed additional questionnaires a week after each vaccine sub-study clinic visit to tell us which COVID-19-specific vaccine they received and any reactions experienced.

Participation in the sub-study ended 28 days after receiving the second dose of a COVID-19-specific vaccine.

Learn more about BCOS

brace nov news thumb 2021

Introducing BCOS

The BCG vaccine trial joins global race to better understand COVID-19 variants. It will also look at whether BCG vaccine improves the immune response to Pfizer, AstraZeneca and CoronaVac vaccines.

Read more

brace nov news thumb 2021

The global race to understand Covid-19 variants

Is it possible to predict who’s susceptible to SARS-CoV-2 variants – despite previous COVID-19 infection or vaccination?

Read more

brace nov news thumb 2021

ABC NewsRadio interview

Dr Nicole Messina, BRACE Biosample and Laboratory Lead, speaks on ABC NewsRadio about the BRACE COVID-19-Specific vaccine sub-study.

Tune in

Professor Nigel Curtis

Want to be part of the global effort to help contain this pandemic?

Donate to the BRACE trial